Acute Myeloid Leukemia, in Relapse

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

CD123 Redirected T Cells for AML in Pediatric Subjects

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)